· In a large, contemporary cohort of 1,467 patients · undergoing biological (37% of patients) or mechanical (63% of patients) valve replacement surgery for definite active infective endocarditis, · bioprosthetic valve replacement was independently associated with higher in-hospital and 1-year mortality, particularly in patients younger than 65 years of age.
Structured abstract Background
Nearly half of patients require cardiac surgery during the acute phase of infective endocarditis (IE). We describe the characteristics of patients according to the type of valve replacement (mechanical or biological), and examine whether the type of prosthesis was associated with in-hospital and 1-year mortality.
Methods and Results

Among 5,591 patients included in the International Collaboration on Endocarditis Prospective
Cohort Study, 1,467 patients with definite IE were operated on during the active phase and had a biological (37%) or mechanical (63%) valve replacement.
Patients who received bioprostheses were older (62 vs 54 years), more often had a history of cancer (9% vs 6%), and had moderate or severe renal disease (9% vs 4%); proportion of health care-associated IE was higher (26% vs 17%); intracardiac abscesses were more frequent (30% vs 23%). In-hospital and 1-year death rates were higher in the bioprosthesis group, 20.5% vs 14.0% (p=0.0009) and 25.3% vs 16.6% (p<.0001), respectively.
In multivariable analysis, mechanical prostheses were less commonly implanted in older patients (odds ratio: 0.64 for every 10 years), and in patients with a history of cancer (0.72), but were more commonly implanted in mitral position (1.60).
Bioprosthesis was independently associated with 1-year mortality (hazard ratio: 1.298).
Conclusions
Patients with IE who receive a biologic valve replacement have significant differences in clinical characteristics compared to patients who receive a mechanical prosthesis. Biologic valve replacement is independently associated with a higher in-hospital and 1-year mortality, a result which is possibly related to patient characteristics rather than valve dysfunction. There are limited data to support the choice of either type of prosthesis in IE. [6] The characteristics of patients receiving biological or mechanical prosthesis and the association between type of valve prosthesis and outcome are not clearly defined. Thus, the objectives of this observational study were to describe the characteristics of patients according to the type of prosthesis and to examine the relationship between prosthesis type and 1-year mortality. 
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Patient Selection, Data Collection and Outcomes
Patients were identified prospectively and consecutively enrolled in ICE-PCS if they met criteria for possible or definite IE based on modified Duke criteria. [9] Only the first episode of IE recorded for an individual patient was used in the analysis. Patients with definite IE who underwent valve surgery during the active phase of IE and who had biological or mechanical valve replacement were included. Exclusion criteria were: age <18 years old;
intravenous drug user; patients treated with valve repair rather than replacement or who received a homograft or an autograft; patients receiving both a mechanical prosthesis and a bioprosthesis and patients whose 1-year survival data were missing.
A standard case report form was used at all sites to collect data. The case report form included 275 variables and was developed by ICE according to standard definitions. [7] Data were collected during the index hospitalization and then entered at the coordinating centre or by site investigators using an Internet-based data entry system. Clinical characteristics
including demographics, comorbid conditions, pre-existing valvular conditions, details regarding the current episode of IE (including source of acquisition, [10, 11] microbiology and echocardiography findings, complications, management, and outcome) were collected. All sites were queried to obtain 1-year outcome data for survival, with use of national death indices, medical records, or patient contact, as available.
Statistical analysis
The outcomes of interest in this study were in-hospital and 1-year mortality. Data are presented as means (standard deviations) for continuous variables and as frequencies All tests were 2-sided, and statistical significance was determined at the 0.05 level. All statistical analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC).
RESULTS
There were 5,668 patients with definite and possible IE enrolled in the ICE-PCS.
Based on pre-specified inclusion and exclusion criteria for this study, 1,467 patients, including 917 (63%) who received mechanical prostheses only and 550 (37%) who received bioprostheses only, were included in this study (Figure 1 ). 
Only three variables independently predicted the implantation of a biological or a mechanical prosthesis. Compared to bioprostheses, mechanical prostheses were less commonly implanted in patients with increased age (OR: 0.64 for every 10 years; 95% CI:
0.561 -0.733), and in patients with a history of cancer (OR: 0.72; 95% CI: 0.526 -0.979), but were more commonly utilized in mitral valve replacements (OR: 1.60; 95% CI: 1.289 -1.996).
Multivariable analysis of 1-year mortality predictors is presented in Table 2 .
Bioprosthesis use was independently associated with 1-year mortality; the risk of death was increased by 30% (hazard ratio: (Figure 2 ).
After covariate adjustment, 1-year mortality estimates for biologic and mechanical prostheses were 24.7% and 20.5%, respectively (p = 0.0362).
DISCUSSION
In the present study, 1,467 patients received valve prostheses during the acute phase of IE with 37% receiving biologic valve replacement and 63% a mechanical prosthesis. Both inhospital and one-year mortality were higher in the bioprosthesis group. The higher mortality associated with bioprosthesis extended beyond the in-hospital acute phase of IE, and was independently associated with 1-year mortality in multivariable analysis. These results have relevance to current clinical practice, as biologic valve replacements were used in approximately 60% of valve replacement surgeries for IE in the United States from 2002 to 2008. [12] A C C E P T E D M A N U S C R I P T
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A few randomized trials have compared the outcome of biological versus mechanical prostheses, but none have included patients with IE. [13] [14] [15] In a Veterans' Administration trial involving 575 patients undergoing single aortic or mitral valve replacement randomized to receive a biological or mechanical valve, the 15-year mortality after aortic valve replacement was higher with a bioprosthesis than mechanical prosthesis, but not after mitral valve replacement. [14] Bloomfield et al. randomized 533 patients to biological or mechanical prosthesis, and there was a non significant trend toward higher mortality after 12 years with the bioprosthesis. [13] However, in a meta-analysis of three trials, 5-year and 11-year mortality were not statistically different between the two types of prosthetic valves. [16] Other observational studies have compared the results of biologic or mechanical valve prosthesis for IE. In a previous study of 185 patients who received a valve prosthesis during the acute phase of IE, the 4-year mortality was higher in the bioprosthesis group. [17] In a small study of patients undergoing aortic valve replacement for aortic valve IE, 5-year mortality of patients who received biologic replacements (bioprostheses or homografts) was two-fold higher than for patients who received mechanical valve replacement, yet the increased mortality was evident only in patients less than 65 years of age. [18] Other studies have found no significant difference in mortality for biologic compared to mechanical valve replacement, but a higher rate of reoperation in younger patients who received biologic prosthesis. [19, 20] In a recent, retrospective study of patients on dialysis with IE who underwent valve surgery, no difference in longer term mortality was evident between type of valve prosthesis. [21] However, this cohort included patients treated with surgery beyond the acute phase of IE and the very high one-year mortality rate may have overshadowed any valve-related effect. [21] In the current study, the increased in-hospital and 1-year mortality associated with biologic valve replacement was evident only in patients younger than 65 years of age. This This study has several other limitations. Since this is an observational study, the results are subject to selection bias such that unidentified variables may have influenced surgical decision-making regarding the type of prosthesis implanted. We could not ascertain whether in-hospital or 1-year mortality was due to a mechanical cardiac, infectious, or unrelated cause. Data regarding the use of anticoagulation after valve replacement and relapse of IE were not collected in this study, yet may have influenced outcome.
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In conclusion, in a large, contemporary cohort of patients undergoing valve replacement surgery for active IE, bioprosthetic valve replacement was associated with higher in-hospital and 1-year mortality, particularly in patients younger than 65 years of age. Further studies are needed to determine factors related to type of prosthesis implanted in the setting of active IE and the valve-related outcome of these interventions. No significant difference between the two groups for the following parameters: 
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